Nuvectis Pharma, Inc. (NVCT) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$19.71

From 52W high−35.26%

Volume372285.00

Market cap$602.94M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$19.71

From 52W high

−35.26%

Volume

372285.00

Market cap

$602.94M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−20.1x

P/E (TTM)

—

RSI (14)

38.0

MomentumView details →

1D Return

−4.50%

YTD Return

+132.05%

SummaryUpdated Jun 1, 2026

Nuvectis Pharma, Inc. (NASDAQ:NVCT) is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Fort Lee, New Jersey. The company went public in February 2022 and focuses on developing precision medicines to treat serious unmet medical needs in oncology. Nuvectis operates as a research and development-focused biotech firm with two primary drug candidates in its pipeline, targeting novel pathways in cancer treatment.

Ask drillr about Nuvectis Pharma, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−20.1x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

66.4x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−306.61%

ROA (TTM)

−124.45%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−13.91%

FCF YoY

−57.21%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−18.92%

EBITDA YoY

−28.68%

MomentumView details →

1D Return

−4.50%

YTD Return

+132.05%

1Y Return

+210.09%

RSI (14)

38.0

vs 50D SMA

−16.98%

vs 200D SMA

+18.64%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

1.68x

Quick Ratio

1.68x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.02

EPS Surprise

−322.06%

Beats (12Q)

2/12

Next Q EPS Est

−$0.25

Avg Surprise (4Q)

−85.62%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−27.85M

Op. CF (TTM)

−19.51M

Next earningsNov 4, 2026 →

Latest newsMore news →

Nuvectis Pharma announced that it will host a conference call and webcast on November 4, 2026, at 8:00 a.m. ET to discuss business progress and third-quarter financial results.2d ago

Nuvectis Pharma, Inc. reported Phase 1b study data for NXP200, with objective response rates of 40.0% in high-grade glioma and 42.9% in low-grade glioma.9d ago

Similar companies

aTyr Pharma, Inc.ATYR Bicara Therapeutics Inc. Common StockBCAX Adlai Nortye Ltd.ANL SL Science Holding Limited Ordinary SharesSLBT DBV Technologies S.A.DBVT DiaMedica Therapeutics Inc.DMAC Find similar companies →

Latest newsMore news →

Nuvectis Pharma announced that it will host a conference call and webcast on November 4, 2026, at 8:00 a.m. ET to discuss business progress and third-quarter financial results.2d ago Nuvectis Pharma, Inc. reported Phase 1b study data for NXP200, with objective response rates of 40.0% in high-grade glioma and 42.9% in low-grade glioma.9d ago